Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study - Wikidata - awgldk - TriplyDB

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study

http://www.wikidata.org/entity/Q34481365

about

Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.Immigrant women living with HIV in Spain: a qualitative approach to encourage medical follow-up Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.How do outcomes compare between women and men living with HIV in Australia? An observational study.Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection Caring for women living with HIV: gaps in the evidence.Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV.Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064).Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study.The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

P2860

Q34153838-76B3FD2D-9AC0-471B-B102-FC32D43F2364 Q34472398-31B90F58-2D94-4970-81F8-390A0180C61C Q34517582-EF098F7A-1FFC-4FBD-8A10-0A0DC417DE12 Q35896106-820EE657-3F0A-4C4D-BC93-133F74029BAB Q35908984-3312D8AA-0590-4F24-9692-8B66A9C605D3 Q35944787-5F853A9D-2ACA-42FE-8543-66DC979FFE8E Q36157703-6A34A214-56B5-4ECC-9240-C8D5C84625E5 Q36974067-0355721B-2C4A-4397-BF7E-923BA8000B74 Q37212049-FE4FECA2-2A87-4BC1-9D2F-4DB1C513EF60 Q37410986-35F2F1BD-ACE6-42FB-8A93-E8970D47D9AD Q37691625-BB12CE47-899A-48E0-A364-E756CBD2A7EA Q37701086-ABB92991-69F8-4F25-9C5E-A3EA3D6CDA98 Q38853255-A420F319-33B4-4A3B-90B4-9B8D0D5DB9F8 Q39372748-D3A4F74E-9223-4806-80D4-43BF84A55D94 Q42205021-67FCDBF2-E525-4EEE-896B-FB951C769B43 Q45746984-E70AF29B-7608-4D02-A814-759DDEF90C5B Q46173618-745D3BB7-3187-4256-9E1A-01955C7D55BD Q57180790-C4123C9A-CA15-4D38-B156-B2391012E932

P2860

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study

http://www.wikidata.org/entity/Q34481365

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@ast

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@en

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@nl

type

label

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@ast

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@en

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@nl

prefLabel

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@ast

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@en

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@nl

P1433

Q34481365-342DE1E1-DB73-4879-9058-F46467E5BB04

P1476

Q34481365-2A1B5C2B-F70A-4AC7-84B0-F3840F7E753B

P2093

Q34481365-00031222-B735-42AF-AECE-8DD0A2414006

Q34481365-3CD42626-66F1-47F3-A093-53E3A3E442F0

Q34481365-6BF54E97-5ED3-42C9-9624-1A47B64B76A1

Q34481365-77E61667-DB92-4000-846A-46C7FF337A86

Q34481365-80DF55BF-5D28-4ED4-848A-8BC859FDFFBE

Q34481365-AE68F28A-6389-4A0B-84AF-6D6B778ED5C4

Q34481365-C2457106-207C-467C-8154-BC3BA5F2B939

P2860

Q34481365-0DF489F7-8756-4DAA-82C7-AD97AA11E95C

Q34481365-16D0FED1-2E50-45AD-8679-1D00728096C4

Q34481365-1F2D5F83-F0D3-480F-907F-B911BABF29C0

Q34481365-28F544BE-1B56-4DFB-9521-AB7876BD4EAE

Q34481365-312AA49F-242E-4397-8A32-9AB78D0F488A

Q34481365-682EAE7B-27E6-4B35-A540-506E8CAA9C9A

Q34481365-6C399959-FB22-468B-9B76-6788AD2C88FF

Q34481365-7D7EB058-E2EF-4615-B14B-18747C3235C5

Q34481365-828F4633-C32F-4595-813A-43C66A0550C7

Q34481365-85ED3B84-53CB-461C-B2B4-338BAA317C81

P304

Q34481365-B283CCBB-9383-4149-8CCD-6F8B12444BC6

P31

Q34481365-7474787D-F97F-43F0-80C3-E8998A8CC03E

P356

Q34481365-9A437C3C-82A8-4D64-879C-4F22CEB88EE5

P407

Q34481365-97C7B50C-B353-477C-ABBE-83917035E78B

P433

Q34481365-01F91232-7F81-449A-B045-BEF867A86277

P478

Q34481365-53321DCA-C191-42F9-9E2C-86F5EAA4A534

P577

Q34481365-5532CECB-EF3F-427C-BD72-530EC0D588FD

P5875

Q34481365-8620DC51-DCB8-4060-8E88-99B49C71A6D3

P698

Q34481365-55E69571-D219-4CA0-8865-E5471D535225

P932

Q34481365-4E438D63-5F8E-4D75-9D16-15EFA975A3A6

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Comparative gender analysis of ...... t 96 weeks in the CASTLE study

@en

P2093

Donnie McGrath

http://www.w3.org/2001/XMLSchema#string

Jonathan Uy

http://www.w3.org/2001/XMLSchema#string

Judith Absalon

http://www.w3.org/2001/XMLSchema#string

Kathleen E Squires

http://www.w3.org/2001/XMLSchema#string

Louise Sheppard

http://www.w3.org/2001/XMLSchema#string

Margaret Johnson

http://www.w3.org/2001/XMLSchema#string

Rong Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

Class-sparing regimens for initial treatment of HIV-1 infection.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women.

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.

Barriers to antiretroviral medication adherence in HIV-infected women.

P304

363-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKQ457

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49674114

http://www.w3.org/2001/XMLSchema#string

P698

21148235

http://www.w3.org/2001/XMLSchema#string

P932

3019087

http://www.w3.org/2001/XMLSchema#string